Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased levels of leucocytic angiotensin converting enzyme 2 (ACE2) relate to atherosclerosis in patients with chronic kidney disease (CKD).
|
30326474 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies demonstrated that deficiency of angiotensin-converting enzyme 2 (ACE2) augmented angiotensin II (AngII)-induced atherosclerosis and abdominal aortic aneurysm (AAA) formation in hypercholesterolemic mice.
|
30850299 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, circulating ACE2 has been shown to be associated with silent atherosclerosis and CV outcomes in CKD patients.
|
28413960 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease.
|
28186543 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Application of NaHS, an H<sub>2</sub>S donor considerably attenuated the severity of atherosclerosis with upregulating carotid expression of ACE2, thus converting pro-atherosclerotic angiotensin II (Ang II) to anti-atherosclerotic angiotensin 1-7 (Ang-(1-7)).
|
29066981 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accelerated atherosclerosis was studied in vivo, and atherosclerosis was induced in apoE-deficient mice which were divided randomly into four groups that received respectively a ACE2 gene transfer, Ad-ACE2, Ad-EGFP, Ad-ACE2 + A779, an Ang-(1-7) receptor antagonist, control group.
|
25721616 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether leukocytic ACE2 influenced atherosclerosis, irradiated low-density lipoprotein receptor-deficient male mice were repopulated with bone marrow-derived cells from Ace2(+/y) or Ace2(-/y) mice and fed a high-fat diet for 3 months.
|
21252069 |
2011 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest a differential regulation of ACE2 activity during the progression of atherosclerosis and suggest that this novel molecule of the renin-angiotensin system may play a role in the pathogenesis of atherosclerosis.
|
18498093 |
2008 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis.
|
18403726 |
2008 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
To this aim, we performed in vitro gain and loss of function experiments in endothelial cells and evaluated in vivo angiogenesis and atherosclerosis in apolipoprotein E-knockout mice treated with AdACE2.
|
18660448 |
2008 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To this aim, we performed in vitro gain and loss of function experiments in endothelial cells and evaluated in vivo angiogenesis and atherosclerosis in apolipoprotein E-knockout mice treated with AdACE2.
|
18660448 |
2008 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
L-NG monomethyl arginine induced greater constriction in patients with the ACE DD compared with ACE II genotype (coronary blood flow -10 +/- 4% vs. 11 +/- 5%, p = 0.003, ACE DD vs. II and diameter constriction -6.3 +/- 1.2% vs. -1.9 +/- 1.2%, p = 0.01, respectively, in patients with atherosclerosis).
|
11079661 |
2000 |